🔴 Ionis Pharmaceuticals is trading 4% down today after pelacarsen’s Phase 3 trial missed its cardiovascular endpoint

Ionis Pharmaceuticals is trading 4% down at $49.37 amid continued investor reassessment of partner Novartis’ September 4 announcement that pelacarsen’s Phase 3 Lp(a)HORIZON study missed its primary cardiovascular endpoint.

• The trial failed to show reduced cardiovascular events versus placebo despite lowering Lp(a) levels.
• The decline extends the recent selloff; shares closed at $51.44 on September 14 after several consecutive lower sessions.
• Broader biotechnology weakness is adding pressure, but the failed trial remains the clearest company-specific catalyst.